University of California San Francisco
Give to UCSFA new fast-track review for UCSF gene therapy could help more kids with deadly Artemis-SCID disease get life-saving treatment sooner.
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types.
Many patients with COVID-19 develop brain fog and other cognitive symptoms months later. Their cerebrospinal fluid may hold clues to why this is happening.
UCSF researchers found that cancers from different parts of the body are immunologically similar to one another. They described 12 classes of "immune archetypes" to classify cancer tumors, which can provide unique strategies for enhancing patients’ choice of cancer immunotherapies.
A new study led by scientists at UCSF's Quantitative Biosciences Institute and University College London found that the Alpha variant of SARS-CoV-2 ramped up production of a protein that it uses to stifle infected cells’ immune-stimulating signals, helping it evade immune detection and accelerate its transmission.
A concerted research effort gave UCSF scientists early insight into long COVID. It also showed patients that they weren’t in the fight alone.
UCSF researchers have discovered a new type of cell that may be responsible for the exaggerated immune response behind inflammatory disease.
UCSF’s research has been ranked among the top in the world, according to the latest U.S. News & World Report’s Best Global Universities 2022 rankings.
Three adolescents who had mild or asymptomatic COVID-19 developed sudden severe psychiatric symptoms. A recent study into their immune responses identifies a potential mechanism by which these symptoms emerge.
Trauma leaves marks on the body, as well as the mind. UCSF scientists have identified an immune signature to indicate which patients will respond best to therapy.
Most patients on immunosuppressive drugs for chronic inflammatory conditions, like rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease, can still produce antibodies after receiving the mRNA COVID-19 vaccines, researchers at UCSF and Washington University have concluded.
We spoke to UCSF virologist Nadia Roan, PhD, about the latest developments in our knowledge of the Delta variant, including how the new variant spreads so efficiently, whether it causes more serious illness, and why she thinks vaccines will hold the line.